HCC patients are not eligible for LT, often because their disease burden exceeds LT criteria. Screening for HCC in high-risk patients detects HCC earlier in the disease course, increases the likelihood of potentially curative treatment, and improves survival. (2) (3) (4) (5) Ultrasound (US) screening has also been found to be cost-effective in populations at high risk for developing HCC. (6) On the basis of these data, the 2010 American Association for the Study of Liver Diseases (AASLD) HCC guidelines recommend screening with biannual US for populations whose yearly HCC incidence exceeds 1.5%. (7) There is a paucity of data on factors associated with failure of US as a screening test for HCC. Advanced cirrhosis, the presence of ascites, and obesity may represent some of the factors potentially limiting the ability of US to detect a small HCC. The epidemic of obesity and metabolic syndrome has resulted in a rising prevalence of nonalcoholic steatohepatitis (NASH), estimated to be 12% in a middle-aged population in the United States. (8) Recent studies have found a yearly HCC incidence of 2.6%-2.7% in patients with NASH cirrhosis. (9, 10) Investigators have speculated that US may perform poorly in patients with fatty livers and high body mass index (BMI). (11) However, the large surveillance cohorts (12, 13) contributing to a pooled US surveillance sensitivity of 0.94 were conducted (14) in a country with a 3-fold lower prevalence of obesity than is seen in the United States, (15) and they did not evaluate NASH or BMI. Furthermore, the only randomized controlled trial demonstrating efficacy of US surveillance was limited to patients with hepatitis B virus (HBV), and similarly, it did not evaluate BMI. (3) Del Poggio et al. evaluated factors affecting efficacy of US surveillance, and they found surveillance interval, male sex, higher cirrhosis class, and alpha-fetoprotein (AFP) < 200 ng/mL to be independently associated with surveillance failure. (16) No study has yet addressed the effect of NASH and BMI on US sensitivity for detection of HCC.
In the present study, we aimed to investigate the failure rate of US for detecting liver lesions in patients referred for LT with known HCC compared with computed tomography (CT) or magnetic resonance imaging (MRI) and to identify factors associated with US failure.
Patients and Methods

StUDY PoPULatioN
At a single high-volume LT center, we collected a retrospective cohort of all adult patients presenting for initial LT evaluation with a diagnosis of HCC over the period from January 2007 to February 2016. On the day of their LT evaluation, patients underwent an abdominal US that was performed and read at our center. Patients also have recent cross-sectional imaging for staging, which although not always performed at our center, was reviewed by our radiologists. Imaging was reviewed at our center's multidisciplinary tumor board attended by transplant hepatologists, transplant surgeons, oncologists, and diagnostic and interventional radiologists with expertise in abdominal imaging.
The diagnosis of NASH was defined as an etiology of liver disease based on the standard definition of either biopsy confirmation or lack of an alternate cause of liver disease in the presence of metabolic risk factors including BMI ≥ 30 kg/m 2 (or BMI ≥ 25 kg/m 2 for Asians). The diagnosis of HCC was based on Liver Imaging Reporting and Data System (LI-RADS), (17) a set of imaging criteria created to standardize the reporting of HCC imaging findings. Patients were included if they had at least 1 untreated LI-RADS with 4 or 5 lesions at least 1 cm in size. For imaging obtained prior to the implementation of LI-RADS at our center, the diagnosis of HCC was based on quadruple-phase contrast-enhanced CT or MRI showing a lesion at least 1 cm in size with arterial phase hyperenhancement and delayed phase washout or if a lesion showed growth by ≥3 mm within 6 months when assessed by the same imaging technique. (18) The cross-sectional study closest in time to the index US was used for this analysis. Patients were included if they had at least 1 untreated lesion meeting these imaging characteristics. Patients were excluded if they did not have a US, did not have cross-sectional imaging within 3 months before or after their US, or had an insufficiently detailed read of their imaging to compare detection of individual nodules.
MeaSUReMeNtS
US and CT or MRI findings were directly compared. Other data collected included ascites on US (none/ small/moderate/large), the mechanism and date of initial HCC diagnosis, and type of previous locoregional therapy (LRT). BMI, serum total bilirubin, international normalized ratio for prothrombin time, creatinine, AFP, albumin, and encephalopathy measured at the time of the transplant evaluation were also collected. BMI was dichotomized at 30 kg/m 2 ; Model for End-Stage Liver Disease (MELD) was dichotomized at the sample median of 11.
StatiStiCaL aNaLYSiS
Per-patient US failure was defined as US detection of none of the lesions recorded on CT/MRI. Pernodule US failure was defined as failure to detect the specific nodule described on CT/MRI. Sensitivity of US was calculated against a CT/MRI gold standard both per-patient and per-nodule. Univariate logistic regression marginal effects were used to assess single predictor effects on sensitivity. Multivariate logistic regression tested for independent predictors of US failure.
Because the cohort included imaging read prior to the institution of LI-RADS criteria for HCC diagnosis, a sensitivity analysis stratified predictor effects by Original article | 1173 time before and after implementation of these criteria at our center in December of 2012.
This study was approved by the committee for human research (institutional review board 12-09018).
results
CHaRaCteRiStiCS oF tHe StUDY PoPULatioN
Over a period of 9 years, 1007 patients with HCC presented for phase 1 LT evaluation at our center. Of these, 352 (35%) were included in the study (Fig. 1) . The most frequent reason for exclusion was indeterminate or previously treated lesions (47%) and imaging missing or >3 months apart (10%). Of the included group, 69% had CT, and 31% had MRI. Of the included patients, 21 (6%) had NASH documented as the primary etiology of liver disease, and 10% had moderate or large ascites on US. Patients had a median MELD of 11 (interquartile range [IQR], 9-14); 35% of patients had a BMI ≥ 30 kg/m 2 . Of patients with NASH, 73% had diabetes, median hemoglobin A1c was 6.8 (IQR, 5.8-6.8), and 79% had dyslipidemia. Of the patients with NASH, 15 (71%) had a BMI ≥ 30 kg/m 2 . Patient and disease characteristics are detailed in Table 1 .
PeR-PatieNt US SeNSitivitY
Median time from US to CT/MRI was 3 days (IQR, -6 to 39). Overall, US failed to detect 18% of patients with HCC; 88% of failures had a single nodule on cross-sectional imaging. On univariate analysis, US sensitivity decreased by 0.25 in NASH versus other etiologies for liver disease (sensitivity, 0.59; 95% confidence interval [CI], 0.39-0.80 versus 0.84; 95% CI, 0.80-0.88; P = 0.003). Higher BMI was associated with higher failure rates: BMI ≥ 30 kg/m 2 decreased sensitivity by 0.10 (sensitivity, 0.76; 95% CI, 0.68-0.83 versus 0.86, 95% CI, 0.82-0.91; P = 0.01). For BMI of 35-40 kg/m 2 (n = 11), US sensitivity was 0.71 (95% CI, 0.55-0.87; difference versus BMI < 35 kg/m 2 = -0.10, 95% CI, -0.22 to 0.02; P = 0.09). For BMI ≥ 40 kg/m 2 (n = 15; failure n = 2), US sensitivity was 0.87 (95% CI, 0.69-1.03; difference versus BMI < 40 kg/m 2 = 0.049, 95% CI, -0.17 to 0.27; P = 0.67).
BMI remained a significant predictor of US failure among patients with disease etiologies other than NASH (Table 2) . Each unit increase in BMI was associated with decreased odds of HCC detection (OR, 0.94; 95% CI, 0.90-0.99; P = 0.02). An additional 3 patients had cryptogenic cirrhosis and BMI ≥ 30 kg/ m 2 . When included in a modified NASH category, this remained a significant predictor of US failure (Table 2) . NOTE: Data are given as n (%) or median (IQR).
Presence of moderate or large ascites and receipt of previous LRT were not associated with decreased sensitivity (Table 2) . Increasing age was also not associated with decreased sensitivity (odds ratio [OR], 1.01; 95% CI, 0.97-1.04; P = 0.73). HCC was most frequently discovered by screening with CT or MRI (39%), followed by US screening (31%) and AFP screening (14%).
In this cohort, 59% of patients had cross-sectional imaging after implementation of LI-RADS in December 2012 at our center. After stratifying by LI-RADS utilization, NASH remained a significant predictor of decreased US sensitivity (Table 3) . On multivariate analysis, only NASH remained an independent predictor of US failure (OR, 0.32; 95% CI, 0.13-0.81; P = 0.02; Table 4 ).
In this study, 164 (47%) patients had AFP ≥ 20 ng/ mL at the time of US. The addition of AFP to US increased sensitivity to 0.89 (versus 0.82; P = 0.007). In patients with NASH, sensitivity of US and AFP ≥ 20 ng/mL combined remained significantly lower than in patients without NASH (sensitivity, 0.72 versus 0.91, respectively; P = 0.008). In patients with BMI ≥ 30 kg/ m 2 , the addition of AFP increased sensitivity to 0.89 versus 0.90 in patients with BMI < 30 kg/m 2 (P = 0.98).
PeR-NoDULe US SeNSitivitY
There were 501 nodules in the cohort: an average of 1.4 per patient. US failed to detect 26% of nodules. US was less sensitive in patients with MELD ≥ 11, BMI ≥ 30 kg/m 2 , and NASH (Table 5 ). Sensitivity of US decreased with decreasing nodule size (OR test for linear trend among size by cm; P < 0.001). US was less likely to detect nodules 1-2 cm in size compared with larger lesions, with a sensitivity of 0.65 (n = 142; 95% CI, 0.59-0.71) versus 0.80 (n = 359; 95% CI, 0.76-0.84; P < 0.001; Fig. 2 ). Excluding nodules < 2 cm in size, 313 remained with a median size of 2.8 cm (IQR, 2.3-3.7 cm). Per-nodule sensitivity was 0.81 (versus 0.74 for all nodules). NASH remained a significant predictor of US failure in this subgroup (sensitivity, 0.58 versus 0.82; P = 0.007). Among these 501 nodules, 143 were found in the left lobe and 340 in the right; 18 reads did not specify laterality. US failure rate did not vary by nodule location (left lobe, 0.22; right lobe, 0.28; P = 0.20).
On multivariate analysis, nodule size, NASH, and MELD ≥ 11 remained independently predictive of US sensitivity (Table 6 ).
Discussion
NASH is estimated to have a yearly HCC incidence of 2.6%-2.7% (9, 10) and is the most rapidly growing Original article | 1175 disease etiology among LTs performed for HCC. (19) According to AASLD recommendations, (7) patients at high risk for developing HCC should be screened with US at 6-month intervals. However, the trials forming the backbone of evidence for HCC screening did not include NASH. (3, 20) These trials may also overestimate the efficacy of US screening in the United States, where 35% of adults have a BMI ≥ 30 kg/m 2 . (21) In this country, an increasing proportion of patients screened according to the 2010 AASLD guidelines will be undergoing screening with tools that have not been validated in their population. To our knowledge, this is the first study to consider the effect of NASH and patient BMI on US sensitivity for HCC detection. This study evaluated the sensitivity of US compared with cross-sectional imaging in patients with HCC presenting for LT evaluation. We found that US is inferior to cross-sectional imaging in patients with NASH, potentially missing 41% of those afflicted with HCC. Our data also suggest that US misses 10% more nodules in patients with BMI ≥ 30 kg/m 2 compared with patients with lower BMIs. The overall estimate of US sensitivity of 0.82 is consistent with prior reports of higher sensitivity of cross-sectional imaging when compared with US, (22) though it is higher than the pooled diagnostic US sensitivity estimate of 0.61 (95% CI, 0.44-0.76) reported by Colli et al. (23) Our finding that US has decreased sensitivity for lesions <2 cm is consistent with prior data. (14, 22, 23) Excluding these small nodules did not affect our major findings. Finally, among the patients included in our study, HCC was diagnosed by screening US in only 31%, suggesting that providers recognize the suboptimal performance of US for detecting HCC in this population.
Our findings suggest that cross-sectional imaging should be considered in HCC screening programs for patients with NASH or obesity. First-line use of cross-sectional imaging is more costly and is associated with higher risk due to intravenous contrast (24) and radiation exposure. (25) Though there are no data yet on the performance of CT or MRI in a surveillance setting, comparison of imaging to explant pathology and histologic findings has previously demonstrated increased sensitivity of CT or MRI versus US. (22, 26) In contrast to combining US with AFP, (27) incorporating cross-sectional imaging would likely increase HCC detection without as large an increase in false-positives, and it may prove cost-effective in selected patient populations. At our center, we recommend that HCC surveillance be conducted with alternating US and CT/MRI every 6 months for patients with decompensated cirrhosis on the waiting list for LT. This approach is supported by a higher rate of US missing HCC in patients with a higher cirrhosis class in a previous report, (16) as well as by a recent study finding a significant proportion of USs in patients with NASH, BMI > 35 kg/m 2 , and Child-Pugh class C to be technically inadequate for HCC screening. (28) Finally, adding AFP to US for HCC screening has been controversial, and this study is not designed to address this issue. Nevertheless, adding AFP to US appears to be of lesser value for NASH versus non-NASH patients in the diagnosis of HCC.
The main limitations of our study are those of generalizability, due to exclusion of a large number of patients with previously treated disease, and to utilization of a nonscreening context. With regard to the former, we do not expect the selection of our cohort to impact the major findings because our results suggest that previous LRT does not impact US sensitivity. BMI, NASH, and laboratory values were similarly distributed among those included and excluded. Unfortunately, the small number of outcomes in the NASH versus BMI subgroups precluded the detailed modeling of this interaction.
With regard to context, we expect that imaging performed during initial LT evaluation would be biased toward greater sensitivity relative to screening US. Radiologists and technicians were not blinded to the diagnosis or to results of previous cross-sectional imaging. In patients initially diagnosed with US, there may also be some selection toward disease visible on US; patients with US failures who present with more advanced disease are excluded by the design of this study. Finally, US is performed by highly experienced technologists at a tertiary center and read by 1 of 6 radiologists with extensive exposure to liver imaging for LT. All of these considerations would be expected to increase our calculated sensitivity, suggesting that performance of screening US in clinical practice may be even worse than our reported results. We are unfortunately unable to assess which technologist performed each study and thus cannot assess whether this specific variable may have affected our results.
This study is also limited by the lack of a pathology gold standard. However, CT and MRI have both been demonstrated to have high specificity for the diagnosis of HCC. (23) Comparing to cross-sectional imaging allows us to use a gold standard that is temporally very close to US, with a low probability of interval disease progression and few episodes of intervening treatment. Finally, the implementation of LI-RADS has not been shown to reduce false-positive HCC diagnoses (29) and did not affect our finding of decreased US sensitivity in NASH.
With the continuing increase in the prevalence of obesity and NASH, larger and prospective studies are needed to determine the optimal approach to HCC surveillance in this population. In the absence of prospective data, we attend to factors limiting the ability of US to detect HCC. These data suggest that US alone is an inadequate screening protocol for patients with NASH or high BMI.
